Voyager Therapeutics, Inc.
VYGR$144M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaLEXINGTON172 employees
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Jun 30, 2026
12dMarket Overview
Stock performance and key metrics
VYGR News
Catalyst Timeline
2 upcoming, 0 past
Phase 1Next
Phase 1 Results - VY1706
Jun 30, 2026AI-detected
For Alzheimer's Disease. Voyager Therapeutics reported that VY1706 was well tolerated with tau reduction in 3-month GLP toxicology data. The IND application is on track for Q2 2026 with clinical trial entry expected in H2 2026.
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Drug Pipeline
No drugs found in this phase.
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply